ES2443817T3 - Método para tratar la deficiencia de vitamina B12 - Google Patents
Método para tratar la deficiencia de vitamina B12 Download PDFInfo
- Publication number
- ES2443817T3 ES2443817T3 ES08844673.7T ES08844673T ES2443817T3 ES 2443817 T3 ES2443817 T3 ES 2443817T3 ES 08844673 T ES08844673 T ES 08844673T ES 2443817 T3 ES2443817 T3 ES 2443817T3
- Authority
- ES
- Spain
- Prior art keywords
- vitamin
- pharmaceutical composition
- snac
- tablet
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002670 vitamin B12 deficiency Diseases 0.000 title claims description 10
- 238000000034 method Methods 0.000 title description 11
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims abstract description 59
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 57
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 57
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 13
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 claims abstract description 12
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims abstract description 6
- 229960002446 octanoic acid Drugs 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 19
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000003086 colorant Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 7
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 6
- 229940045999 vitamin b 12 Drugs 0.000 claims description 6
- 239000003826 tablet Substances 0.000 description 46
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 description 42
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 38
- 235000000639 cyanocobalamin Nutrition 0.000 description 19
- 239000011666 cyanocobalamin Substances 0.000 description 19
- 229960002104 cyanocobalamin Drugs 0.000 description 19
- 238000010521 absorption reaction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- OAYRYNVEFFWSHK-UHFFFAOYSA-N carsalam Chemical compound C1=CC=C2OC(=O)NC(=O)C2=C1 OAYRYNVEFFWSHK-UHFFFAOYSA-N 0.000 description 6
- 229950004289 carsalam Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000011409 Transcobalamins Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940029329 intrinsic factor Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- 108010023603 Transcobalamins Proteins 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960000581 salicylamide Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- OAJLVMGLJZXSGX-SLAFOUTOSA-L (2s,3s,4r,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7 Chemical compound [Co+3].O[C@H]1[C@@H](O)[C@@H]([CH2-])O[C@@H]1N1C2=NC=NC(N)=C2N=C1.[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-SLAFOUTOSA-L 0.000 description 1
- NJEKDCUDSORUJA-UHFFFAOYSA-N 8-[(2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC=CC=C1O NJEKDCUDSORUJA-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- -1 SNAC sodium salt Chemical class 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20108 | 2001-12-21 | ||
| US98489807P | 2007-11-02 | 2007-11-02 | |
| US984898P | 2007-11-02 | ||
| US2010808P | 2008-01-09 | 2008-01-09 | |
| US8356608P | 2008-07-25 | 2008-07-25 | |
| US83566 | 2008-07-25 | ||
| PCT/US2008/082064 WO2009059188A1 (en) | 2007-11-02 | 2008-10-31 | Method of treating vitamin b12 deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2443817T3 true ES2443817T3 (es) | 2014-02-20 |
Family
ID=40591491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08844673.7T Active ES2443817T3 (es) | 2007-11-02 | 2008-10-31 | Método para tratar la deficiencia de vitamina B12 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8022048B2 (https=) |
| EP (1) | EP2215047B1 (https=) |
| JP (1) | JP5555634B2 (https=) |
| KR (1) | KR101344369B1 (https=) |
| CN (1) | CN101952241B (https=) |
| AU (1) | AU2008318423B2 (https=) |
| BR (1) | BRPI0817396C8 (https=) |
| CA (1) | CA2704780C (https=) |
| CL (1) | CL2010000434A1 (https=) |
| CO (1) | CO6280475A2 (https=) |
| DK (1) | DK2215047T3 (https=) |
| ES (1) | ES2443817T3 (https=) |
| MX (1) | MX2010004716A (https=) |
| NZ (1) | NZ585080A (https=) |
| PL (1) | PL2215047T3 (https=) |
| PT (1) | PT2215047E (https=) |
| RU (1) | RU2469728C2 (https=) |
| WO (1) | WO2009059188A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2461803B1 (en) * | 2009-08-03 | 2018-10-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| CA2790708A1 (en) * | 2010-02-24 | 2011-09-01 | Emisphere Technologies, Inc. | Oral b12 therapy |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| RU2602601C2 (ru) | 2011-04-12 | 2016-11-20 | Ново Нордиск А/С | Дважды ацилированные производные glp-1 |
| US8805208B2 (en) * | 2012-02-03 | 2014-08-12 | Tyco Electronics Subsea Communications Llc | System and method for polarization de-multiplexing in a coherent optical receiver |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| EP3542790B1 (en) | 2012-03-22 | 2023-09-13 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| CN104203266B (zh) | 2012-03-22 | 2017-12-26 | 诺和诺德股份有限公司 | Glp‑1肽组合物及其制备 |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| US20140309270A1 (en) | 2013-04-11 | 2014-10-16 | Richard Louis Price | Diagnosis and treatment of a form of autistic spectrum disorder |
| US10098848B2 (en) | 2013-04-11 | 2018-10-16 | Richard Louis Price | Inositol-containing comestible units and methods of treatment using the same |
| US9211284B2 (en) | 2013-04-11 | 2015-12-15 | Richard Louis Price | Diagnosis and treatment of P.R.I.C.E. syndrome |
| US9603812B2 (en) | 2013-04-11 | 2017-03-28 | Richard Louis Price | Treatment of autistic spectrum disorder |
| US20170348417A1 (en) | 2013-04-11 | 2017-12-07 | Richard Louis Price | Treatment of attention deficit disorders and associated symptoms |
| JP6672140B2 (ja) | 2013-05-02 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１化合物の経口投薬 |
| EP3928776B1 (en) | 2016-04-22 | 2025-11-12 | Spoke Sciences, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
| EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| MX2020003330A (es) * | 2017-10-05 | 2020-07-28 | Receptor Holdings Inc | Composiciones de hierbas con mejor biodisponibilidad. |
| CA3078549A1 (en) * | 2017-10-05 | 2019-04-11 | Receptor Holdings, Inc. | Rapid onset and extended action plant-based and synthetic cannabinoid formulations |
| PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
| AU2019385420A1 (en) | 2018-11-19 | 2021-07-08 | Spoke Sciences, Inc. | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| WO1998011900A2 (en) * | 1996-09-18 | 1998-03-26 | Sarill William J | Compositions containing cobalamin and amino acids |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| JP2002533399A (ja) | 1998-12-28 | 2002-10-08 | アラジー リミテッド エルエルシー | アレルギー性疾患に対するシアノコバラミン（ビタミンｂ１２）の治療方法 |
| EP1535625B1 (en) | 1999-04-05 | 2014-01-08 | Novartis AG | Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin |
| EP1175390B1 (en) * | 1999-04-05 | 2005-02-02 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
| ES2386263T3 (es) | 2000-03-21 | 2012-08-14 | Emisphere Technologies, Inc. | Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato |
| US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| PL211976B1 (pl) | 2001-06-01 | 2012-07-31 | Novartis Ag | Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji |
| EP1420827B8 (en) | 2001-08-17 | 2009-12-23 | Novartis AG | 5-cnac as oral delivery agent for parathyroid hormone fragments |
| US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TW200403052A (en) | 2002-07-17 | 2004-03-01 | Novartis Ag | Use of organic compounds |
| PE20040724A1 (es) | 2002-08-01 | 2004-12-06 | Novartis Ag | Composicion para la administracion oral de calcitonina |
| EP1545477A4 (en) * | 2002-09-13 | 2006-11-22 | Cydex Inc | CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN |
| WO2004087640A1 (en) | 2003-04-04 | 2004-10-14 | Dsm Ip Assets B.V. | Process for the manufacture of n-alkoxalyl-alaninates |
| US6938439B2 (en) | 2003-05-22 | 2005-09-06 | Cool Clean Technologies, Inc. | System for use of land fills and recyclable materials |
| JP3924616B2 (ja) | 2003-06-30 | 2007-06-06 | 独立行政法人物質・材料研究機構 | 微小サイズの温度感知素子を用いる温度計測方法 |
| US20070155664A1 (en) | 2003-07-04 | 2007-07-05 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| ES2330638T3 (es) | 2003-07-11 | 2009-12-14 | Novartis Ag | Composiciones farmaceuticas dosificadas en forma oral que contienen un agente de suministro en forma micronizada. |
| MXPA06000807A (es) | 2003-07-23 | 2006-08-23 | Novartis Ag | Uso de calcitonina en osteoartritis. |
| CN102001962B (zh) | 2004-05-06 | 2013-04-03 | 爱密斯菲尔科技公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶 |
| MX2007001348A (es) * | 2004-08-02 | 2008-03-11 | Bebaas Inc | Composiciones de vitamina b12. |
| WO2006124047A2 (en) | 2004-08-13 | 2006-11-23 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| US20060116334A1 (en) * | 2004-12-01 | 2006-06-01 | Curt Hendrix | Folate based composition for treatment of the cardiovascular system |
| GB0427600D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0427603D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| EP1948159A4 (en) | 2005-11-04 | 2011-10-12 | Genta Inc | PHARMACEUTICAL COMPOSITIONS OF GALLIUM AND METHODS |
-
2008
- 2008-10-31 NZ NZ585080A patent/NZ585080A/en not_active IP Right Cessation
- 2008-10-31 CA CA2704780A patent/CA2704780C/en not_active Expired - Fee Related
- 2008-10-31 EP EP08844673.7A patent/EP2215047B1/en not_active Not-in-force
- 2008-10-31 KR KR1020107010771A patent/KR101344369B1/ko not_active Expired - Fee Related
- 2008-10-31 MX MX2010004716A patent/MX2010004716A/es active IP Right Grant
- 2008-10-31 BR BRPI0817396A patent/BRPI0817396C8/pt not_active IP Right Cessation
- 2008-10-31 RU RU2010118423/15A patent/RU2469728C2/ru active
- 2008-10-31 PL PL08844673T patent/PL2215047T3/pl unknown
- 2008-10-31 WO PCT/US2008/082064 patent/WO2009059188A1/en not_active Ceased
- 2008-10-31 AU AU2008318423A patent/AU2008318423B2/en not_active Ceased
- 2008-10-31 DK DK08844673.7T patent/DK2215047T3/da active
- 2008-10-31 CN CN200880119724.0A patent/CN101952241B/zh not_active Expired - Fee Related
- 2008-10-31 US US12/262,677 patent/US8022048B2/en not_active Expired - Fee Related
- 2008-10-31 ES ES08844673.7T patent/ES2443817T3/es active Active
- 2008-10-31 PT PT88446737T patent/PT2215047E/pt unknown
- 2008-10-31 JP JP2010532292A patent/JP5555634B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-30 CL CL2010000434A patent/CL2010000434A1/es unknown
- 2010-06-02 CO CO10066425A patent/CO6280475A2/es active IP Right Grant
-
2011
- 2011-08-09 US US13/206,090 patent/US8288360B2/en not_active Expired - Fee Related
-
2012
- 2012-09-14 US US13/618,654 patent/US8557792B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2443817T3 (es) | Método para tratar la deficiencia de vitamina B12 | |
| EP2503992B1 (en) | Formulations of bisphosphonates and vitamin d suitable for intermittent intramuscular and subcutaneous administration | |
| TWI429405B (zh) | 用於靜脈營養療法的小兒胺基酸溶液 | |
| US8318805B2 (en) | Modulation of nitric oxide synthases by betaines | |
| ES2398237T3 (es) | Uso de calcitonina en osteoartritis | |
| BRPI0808517A2 (pt) | Administração oral de uma calcitonina | |
| BRPI1009056A2 (pt) | Uso de inecalcitol | |
| EP2338495A1 (en) | Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease | |
| ES2398640T3 (es) | Formulaciones de análogos 14-epi de la vitamina D | |
| EP2919744A1 (en) | Effervescent tablet | |
| ES2629739T3 (es) | Composición farmacéutica estable para el tratamiento de osteoporosis | |
| BR112012021401B1 (pt) | forma de dosagem oral | |
| KR20210087952A (ko) | 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용 | |
| HK1146480B (en) | Method of treating vitamin b12 deficiency | |
| KR102959539B1 (ko) | 칼슘 보충용 조성물 | |
| UA112845C2 (uk) | Склад 14-eпi-аналогів вітаміну d | |
| EA011489B1 (ru) | Средство для лечения простудных заболеваний |